- Details
- Rashid Sayyid and Zach Klaassen analyze a study on the prognostic role of 68 Ga-PSMA-11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy. The researchers note that traditional assessment tools, such as the Prostate Cancer Working Group 3 criteria, often rely on conventional imaging, limiting the ability to differentiate between responders and those with stable di...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a study on the efficacy of combining enzalutamide and abiraterone in treating metastatic castration-resistant prostate cancer (mCRPC) patients. The study, published in the Journal of Clinical Oncology, posits the potential benefit of using both drugs as they counteract each other's resistance mechanisms. Notably, the drugs have been approved separately by th...
|
- Details
- In this discussion between Rashid Sayyid and Zach Klaassen, the experts review the outcomes of the JAVELIN Bladder 100 trial. The trial investigated the effects of Avelumab, a first-line maintenance therapy for advanced urothelial carcinoma, and involved 700 patients who showed no disease progression after first-line chemotherapy. Avelumab, in combination with standard care, prolonged median overa...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a study published in Lancet Oncology titled “Radical Cystectomy versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis.” The study compared radical cystectomy and trimodality therapy (TMT) for patients with Muscle-Invasive Bladder Cancer. The authors found that radical cystectomy, t...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss recent findings from the STAMPEDE platform regarding the efficacy of abiraterone acetate plus prednisolone, with or without enzalutamide, for patients with metastatic prostate cancer initiating ADT. Drawing on data from two randomized Phase III trials, the pair examine long-term outcomes. They elaborate on the rationale for combining abiraterone and enzaluta...
|
- Details
- In this Journal Club discussion, Rashid Sayyid and Zach Klaassen discuss the paper "Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review," published in Equity in Cancer Care. The study focuses on the prevalence of genetic testing among different racial groups in the US, and finds significant racial disparities in the use of germline genetic testing for prostate c...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a Journal of Nuclear Medicine publication titled, “The Prognostic Role of 68 Ga-PSMA11 PET-Based Response in Prostate Cancer Patients Undergoing Taxane-Based Chemotherapy.” This cutting-edge research explores the use of PSMA PET/CT imaging as an assessment tool in the biochemically recurrent setting, providing an alternative to conventional imaging methods....
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a publication by the MARCAP Group titled “Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer.” The study aims to validate intermediate clinical endpoints in advanced prostate cancer, which are faster to report, reducing resources required for clinical trials and potentially allowing quicker patient access to effective therapies. The...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the New England Journal of Medicine publication "Patient-Reported Outcomes 12 Years After Localized Prostate Cancer Treatment." The Prostate Testing for Cancer and Treatment (ProtecT) trial evaluated prostatectomy's functional and quality-of-life impacts, radiotherapy with neoadjuvant androgen deprivation, and active monitoring. Patients with low to intermed...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss The New England Journal of Medicine publication "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer." The ProtecT trial invited over 82,000 men between 50 and 69 years, and prostate cancer was diagnosed in 2,664 men, and of these men, just over 1,600 were randomized to either active monitoring, prostatectomy, or radiotherapy...
|
